Search Results for: BioLineRx

Funds raised by Israeli startups

BiolineRX raised $4.39 million; Prilenia raised $62.5 million; C2i Genomics raised $12 million; infiniDome raised $1.6 million; Accellix raised $9.5 million; Nucleai raised $6.5 million;

Posted in Economy & Business | Leave a comment

Orphan status for pancreatic cancer treatment

The European Commission has just granted Orphan drug status to the BL-8040 (Motixafortide) pancreatic cancer treatment from Israel’s BioLineRX (see here). BioLineRX can now receive benefits including EU funding, less regulation, and market exclusivity. https://ir.biolinerx.com/news-releases/news-release-details/biolinerx-receives-orphan-drug-designation-motixafortide-bl-8040

Posted in Israel's Medical Achievements | Leave a comment

Extending lives of pancreatic cancer patients

In the latest Phase 2a trial of the pancreatic cancer treatment from Israel’s BioLineRx (see here) three-quarters of the patients at disease stage 4 were able to get their disease under control. The trial combined BL-8040, KEYTRUDA (Pembrolizumab) and chemotherapy. … Continue reading

Posted in Israel's Medical Achievements | Leave a comment

FDA designation for solid tumor treatment

FDA designation for solid tumor treatment. (TY Atid-EDI) I reported previously (28 Jan) that the AGI-134 solid tumor treatment from Israel’s BiolineRX showed promise. The U.S. FDA has just granted Biological Product Designation for the novel immunotherapy compound. Early trials … Continue reading

Posted in Israel's Medical Achievements | Leave a comment

Good results in pancreatic cancer treatment trials

Israel’s BioLineRx has announced encouraging initial results from its Phase 2a trials of its BL-8040 treatment on patients with metastatic pancreatic cancer. After only five days of treatment the treatment substantially increased the numbers of T-cells fighting the tumors. https://www.prnewswire.com/news-releases/biolinerx-announces-partial-monotherapy-results-from-phase-2a-combat-study-in-pancreatic-cancer-300583808.html

Posted in Israel's Medical Achievements | Leave a comment

Melanoma treatment shows promise

When Israel’s BioLineRx bought UK’s Agalimmune, it also acquired its AGI-134 treatment for solid tumors. BioLineRX has just demonstrated successful results of AGI-134 in two pre-clinical melanoma studies. https://www.prnewswire.com/news-releases/biolinerx-reports-data-at-asco-sitc-conference-showing-complete-tumor-regression-by-agi-134-in-pre-clinical-studies-670669553.html

Posted in Israel's Medical Achievements | Leave a comment

Israeli takeover of UK cancer biotech

Israel’s BiolineRx is buying UK’s Agalimmune,for $6 million. The private UK-based company has developed an innovative, anti-cancer immunotherapy platform. treatment that not only kills the tumor cells at the site of injection, but also brings about a durable, follow-on, anti-metastatic … Continue reading

Posted in Israel's Medical Achievements | Leave a comment

Regenerating liver function

Israel’s BiolineRX in conjunction with Ben Gurion University, Hadassah Medical Center and Novartis has developed a novel treatment BL-1220 that can restore liver function in patients with liver disease and injury. http://www.biolinerx.com/default.asp?pageid=16&itemid=469

Posted in Israel's Medical Achievements | Leave a comment

New treatment for fatty liver disease

Hadasit, the Hadassah Medical Organization’s technology transfer company, and Israel’s BioLineRx are to develop a treatment BL-1210 for non-alcoholic steatohepatitis (NASH) or fatty liver disease.  It modulates the immune system to reduce scarring that leads to cirrhosis.  There is currently … Continue reading

Posted in Israel's Medical Achievements | Leave a comment

Leukemia trial results

Latest reports of Phase II trials of BL-8040 from Israel’s Bioline Rx (see Nov newsletter), show that 38% of patients with acute myeloid leukemia, went into complete remission after just two cycles of the treatment.  All these patients had previously … Continue reading

Posted in Israel's Medical Achievements | Leave a comment